NCT02578979

Brief Summary

Paroxysmal atrial fibrillation is often undetected because characteristics such as short duration, episodic, and frequently asymptomatic nature make it challenging to diagnose at the bedside, leading to suboptimal secondary prevention. It is not uncommon for paroxysmal atrial fibrillation to be undetected in a single electrocardiogram (ECG) on admission. Conventional 24-hour Holter monitoring is often used to detect paroxysmal atrial fibrillation. However, systematic review suggests Holter monitoring will identify atrial fibrillation in only an additional 4.6% of patients, no better than detection rates observed in groups lacking routine monitoring. On the other hand, for ischemic stroke patients with sinus rhythm at baseline but paroxysmal atrial fibrillation still suspected, no recommendation beyond repeated 12-lead ECGs is made in the United Kingdom guideline. Serial 12-lead ECG has been used to detect possible paroxysmal atrial fibrillation among acute ischemic stroke patients and found 15 new cases of atrial fibrillation in 133 acute ischemic stroke patients (11.3%) without atrial fibrillation at baseline. The optimal investigation strategy, including modality, duration of investigation, and patient subgroup remains undefined, not only for efficacy in the detection of atrial fibrillation, but also cost-effectiveness in healthcare systems. The objective of this project is to conduct a pragmatic multicenter randomized controlled trial for the comparison of serial 12-lead ECG once daily for 5 days and 24-hour Holter to detect paroxysmal atrial fibrillation in acute ischemic stroke patients without atrial fibrillation identified by baseline ECG or history.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
826

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2015

Typical duration for not_applicable

Geographic Reach
1 country

6 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2015

Completed
11 days until next milestone

First Submitted

Initial submission to the registry

October 12, 2015

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 19, 2015

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2018

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2018

Completed
Last Updated

July 8, 2019

Status Verified

July 1, 2019

Enrollment Period

2.8 years

First QC Date

October 12, 2015

Last Update Submit

July 4, 2019

Conditions

Keywords

atrial fibrillationischemic strokeelectrocardiogramholter

Outcome Measures

Primary Outcomes (1)

  • Number of atrial fibrillation detected

    within 3 month of stroke onset

Study Arms (2)

ECG for 5 days

EXPERIMENTAL

Patients will receive 12-lead electrocardiogram for 5 days during their hospitalization.

Device: Electrocardiogram

24-h Holter

ACTIVE COMPARATOR

Patients will receive a 24-h Holter during their hospitalization.

Device: Holter

Interventions

Patients will receive electrocardiogram for detecting atrial fibrillation - a 5-day routine ECG.

ECG for 5 days
HolterDEVICE

Patients will receive electrocardiogram for detecting atrial fibrillation - a 24-h Holter.

24-h Holter

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • Cerebral ischemia defined as stroke (sudden focal neurologic deficit lasting \>24 h consistent with the territory of a major cerebral artery and categorized as ischemic) and/or a corresponding lesion on brain imaging
  • Stroke symptoms within 2 days
  • Age ≥65 years

You may not qualify if:

  • History of atrial fibrillation or documented atrial fibrillation prior to randomization
  • Indication for oral anticoagulation at randomization
  • Absolute contraindication for oral anticoagulation at randomization
  • Intracerebral hemorrhage in medical history
  • Implanted pacemaker device or cardioverter/defibrillator
  • End stage renal disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (6)

Chia-yi Christian Hospital

Chiayi City, 600, Taiwan

Location

Dalin Tzu Chi General Hospital

Dalin, 622, Taiwan

Location

Chang Gung Memorial Hospital, Keelung Branch

Keelung, 204, Taiwan

Location

Chang Gung Memorial Hospital, Chiayi Branch

Puzih, 613, Taiwan

Location

National Taiwan University Hospital

Taipei, 100, Taiwan

Location

Chang Gung Memorial Hospital, Linkuo Branch

Taoyuan District, 333, Taiwan

Location

Related Publications (2)

  • Huang WY, Lee M, Sung SF, Tang SC, Chang KH, Huang YS, Lee JD, Lee TH, Jeng JS, Chung CM, Wu YL, Hsieh TT, Ovbiagele B. Atrial fibrillation trial to evaluate real-world procedures for their utility in helping to lower stroke events: A randomized clinical trial. Int J Stroke. 2021 Apr;16(3):300-310. doi: 10.1177/1747493020938297. Epub 2020 Jul 8.

  • Hsieh TT, Lee M, Huang WY, Tang SC, Sung SF, Chang KH, Lee JD, Lee TH, Huang YS, Jeng JS, Chung CM, Wu YL, Ovbiagele B. Atrial fibrillation trial to evaluate real-world procedures for their utility in helping to lower stroke events (AFTER-PULSE): Study protocol for a randomized controlled trial. Contemp Clin Trials Commun. 2017 Jun;6:127-130. doi: 10.1016/j.conctc.2017.04.005. Epub 2017 Apr 26.

MeSH Terms

Conditions

Ischemic StrokeAtrial Fibrillation

Interventions

ElectrocardiographyElectrocardiography, Ambulatory

Condition Hierarchy (Ancestors)

StrokeCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesArrhythmias, CardiacHeart DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Heart Function TestsDiagnostic Techniques, CardiovascularDiagnostic Techniques and ProceduresDiagnosisElectrodiagnosisMonitoring, AmbulatoryMonitoring, Physiologic

Study Officials

  • Meng Lee, MD

    Chang Gung Memorial Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

October 12, 2015

First Posted

October 19, 2015

Study Start

October 1, 2015

Primary Completion

July 31, 2018

Study Completion

October 31, 2018

Last Updated

July 8, 2019

Record last verified: 2019-07

Data Sharing

IPD Sharing
Will not share

Locations